Pertuzumab in Metastatic Breast Cancer
Rachana Patel, PharmD, BCPS, and Jill S. Bates, PharmD, MS, BCOP
From WakeMed Health and Hospitals, Raleigh, North Carolina, and University of North Carolina Hospitals, Chapel Hill, North Carolina
The authors have no conflicts of interest to disclose.
Correspondence to: Rachana Patel, PharmD, BCPS, 101 Manning Drive, Chapel Hill, NC 27514. E-mail: email@example.com
J Adv Pract Oncol 2012;3:391–394 |
DOI: 10.6004/jadpro.2012.3.6.5 |
© 2012 Harborside Press®
Pertuzumab (Perjeta) is indicated in combination with trastuzumab and docetaxel for patients with HER2-positive metastatic breast cancer. Read about key trials that led to its approval, its adverse event profile, and other implications for the AP in oncology.
For access to the full length article, please sign in